How good is ocrelizumab for primary progressive MS?

  Ocrelizumab versus placebo in primary progressive multiple sclerosis Montalban X, Hauser SL, Kappos L, et al; ORATORIO Clinical Investigators. N Engl J Med 2016; doi: 10.1056/NEJMoa1606468 (Epub ahead of print). Abstract BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab,… Read More How good is ocrelizumab for primary progressive MS?

40 very handy and practical neurochecklists

Neurochecklists now contains >1600 checklists on all aspects of neurology. Many checklists come to the rescue only to fill a knowledge gap. Most neurochecklists however address important practical questions or outline pragmatic steps in managing neurological disorders. To illustrate, below is a selection of 40 handy neurochecklists *** Anticoagulants: bridging therapy for surgery Antiepileptic drugs… Read More 40 very handy and practical neurochecklists

What are the emerging drug treatments for Parkinson’s disease (2)?

Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial Schapira AH, Fox SH, Hauser RA, et al. JAMA Neurol 2016; doi: 10.1001/jamaneurol.2016.4467 (Epub ahead of print). Abstract IMPORTANCE: Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its […]… Read More What are the emerging drug treatments for Parkinson’s disease (2)?

What were the most popular posts on The Neurology Lounge in 2016?

The Neurology Lounge started in July 2015 and it is now well into its 2nd year. 2016 was the first complete 12-month calendar period, and during this time the blog received about 25,000 visits and just under 40,000 views. There were visitors from >150 countries around the world with the United States recording the most visits at… Read More What were the most popular posts on The Neurology Lounge in 2016?

What are the emerging drug treatments for Parkinson’s disease (1)

Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial Ferreira JJ, Lees A, Rocha JF, et al; Bi-Park 1 investigators. Lancet Neurol 2016; 15:154-165 Abstract BACKGROUND: Opicapone is a novel, once-daily, potent third-generation catechol-O-methyltransferase inhibitor. We aimed to assess the safety and efficacy of […]… Read More What are the emerging drug treatments for Parkinson’s disease (1)